FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035246543> ?p ?o ?g. }

• W3035246543 abstract "Abstract Background Patients with asthma uncontrolled on inhaled corticosteroids may benefit from umeclidinium (UMEC), a long-acting muscarinic antagonist. Methods This Phase IIb, double-blind study included patients with reversible, uncontrolled/partially-controlled asthma for ≥6 months, receiving ≥100 mcg/day fluticasone propionate (or equivalent) for ≥12 weeks. Following a 2-week run-in on open-label fluticasone furoate (FF) 100 mcg, patients were randomised (1:1:1) to receive UMEC 31.25 mcg, UMEC 62.5 mcg or placebo on top of FF 100 mcg once-daily for 24 weeks. As-needed salbutamol was provided. Primary and secondary endpoints were change from baseline in clinic trough forced expiratory volume in 1 s (FEV 1 ) and clinic FEV 1 3 h post-dose, respectively, at Week 24. Other endpoints included change from baseline in home daily spirometry (trough FEV 1 , evening FEV 1 , morning [pre-dose] and evening peak expiratory flow) over 24 weeks. Safety was assessed throughout the study. Results The intent-to-treat population comprised 421 patients (UMEC 31.25 mcg: n =139, UMEC 62.5 mcg: n =139, placebo: n =143). UMEC 31.25 mcg and 62.5 mcg demonstrated significantly greater improvements from baseline in clinic trough FEV 1 at Week 24 (difference [95% CI]: 0.176 L [0.092, 0.260; p <0.001] and 0.184 L [0.101, 0.268; p <0.001], respectively), clinic FEV 1 3 h post-dose at Week 24 (0.190 L [0.100, 0.279; p <0.001] and 0.198 L [0.109, 0.287; p <0.001], respectively) and mean change from baseline in daily home spirometry over 24 weeks versus placebo. No new safety signals were identified. Conclusions UMEC is a highly effective bronchodilator that leads to improved lung function when administered as a single bronchodilator on top of FF in subjects with fully reversible, uncontrolled/partially-controlled moderate asthma. These data support a favourable benefit/risk profile for UMEC (31.25 mcg and 62.5 mcg). Trial registration GSK study ID: 205832; Clinicaltrials.gov ID: NCT03012061 ." @default.
• W3035246543 created "2020-06-19" @default.
• W3035246543 creator A5007172600 @default.
• W3035246543 creator A5016416819 @default.
• W3035246543 creator A5020135918 @default.
• W3035246543 creator A5025257736 @default.
• W3035246543 creator A5061208260 @default.
• W3035246543 creator A5069835233 @default.
• W3035246543 creator A5078208147 @default.
• W3035246543 creator A5078809766 @default.
• W3035246543 creator A5083879499 @default.
• W3035246543 creator A5090332369 @default.
• W3035246543 date "2020-06-12" @default.
• W3035246543 modified "2023-10-17" @default.
• W3035246543 title "A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids" @default.
• W3035246543 cites W2011828164 @default.
• W3035246543 cites W2026835257 @default.
• W3035246543 cites W2039439214 @default.
• W3035246543 cites W2046179969 @default.
• W3035246543 cites W2062530742 @default.
• W3035246543 cites W2069951540 @default.
• W3035246543 cites W2078690485 @default.
• W3035246543 cites W2086167722 @default.
• W3035246543 cites W2088340248 @default.
• W3035246543 cites W2105402505 @default.
• W3035246543 cites W2112433656 @default.
• W3035246543 cites W2119147796 @default.
• W3035246543 cites W2119922028 @default.
• W3035246543 cites W2123132046 @default.
• W3035246543 cites W2124520988 @default.
• W3035246543 cites W2126325768 @default.
• W3035246543 cites W2128450617 @default.
• W3035246543 cites W2141887601 @default.
• W3035246543 cites W2150634254 @default.
• W3035246543 cites W2162689366 @default.
• W3035246543 cites W2164092307 @default.
• W3035246543 cites W2336917368 @default.
• W3035246543 cites W2340696410 @default.
• W3035246543 cites W2601675613 @default.
• W3035246543 cites W2746473595 @default.
• W3035246543 cites W2749918680 @default.
• W3035246543 cites W2947040724 @default.
• W3035246543 doi "https://doi.org/10.1186/s12931-020-01400-5" @default.
• W3035246543 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7291639" @default.
• W3035246543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32532275" @default.
• W3035246543 hasPublicationYear "2020" @default.
• W3035246543 type Work @default.
• W3035246543 sameAs 3035246543 @default.
• W3035246543 citedByCount "8" @default.
• W3035246543 countsByYear W30352465432021 @default.
• W3035246543 countsByYear W30352465432022 @default.
• W3035246543 countsByYear W30352465432023 @default.
• W3035246543 crossrefType "journal-article" @default.
• W3035246543 hasAuthorship W3035246543A5007172600 @default.
• W3035246543 hasAuthorship W3035246543A5016416819 @default.
• W3035246543 hasAuthorship W3035246543A5020135918 @default.
• W3035246543 hasAuthorship W3035246543A5025257736 @default.
• W3035246543 hasAuthorship W3035246543A5061208260 @default.
• W3035246543 hasAuthorship W3035246543A5069835233 @default.
• W3035246543 hasAuthorship W3035246543A5078208147 @default.
• W3035246543 hasAuthorship W3035246543A5078809766 @default.
• W3035246543 hasAuthorship W3035246543A5083879499 @default.
• W3035246543 hasAuthorship W3035246543A5090332369 @default.
• W3035246543 hasBestOaLocation W30352465431 @default.
• W3035246543 hasConcept C121332964 @default.
• W3035246543 hasConcept C126322002 @default.
• W3035246543 hasConcept C1276947 @default.
• W3035246543 hasConcept C142724271 @default.
• W3035246543 hasConcept C197934379 @default.
• W3035246543 hasConcept C204787440 @default.
• W3035246543 hasConcept C27081682 @default.
• W3035246543 hasConcept C2776042228 @default.
• W3035246543 hasConcept C2776476923 @default.
• W3035246543 hasConcept C2777394947 @default.
• W3035246543 hasConcept C2778375690 @default.
• W3035246543 hasConcept C2779028295 @default.
• W3035246543 hasConcept C2780333948 @default.
• W3035246543 hasConcept C2908647359 @default.
• W3035246543 hasConcept C42219234 @default.
• W3035246543 hasConcept C71924100 @default.
• W3035246543 hasConcept C99454951 @default.
• W3035246543 hasConceptScore W3035246543C121332964 @default.
• W3035246543 hasConceptScore W3035246543C126322002 @default.
• W3035246543 hasConceptScore W3035246543C1276947 @default.
• W3035246543 hasConceptScore W3035246543C142724271 @default.
• W3035246543 hasConceptScore W3035246543C197934379 @default.
• W3035246543 hasConceptScore W3035246543C204787440 @default.
• W3035246543 hasConceptScore W3035246543C27081682 @default.
• W3035246543 hasConceptScore W3035246543C2776042228 @default.
• W3035246543 hasConceptScore W3035246543C2776476923 @default.
• W3035246543 hasConceptScore W3035246543C2777394947 @default.
• W3035246543 hasConceptScore W3035246543C2778375690 @default.
• W3035246543 hasConceptScore W3035246543C2779028295 @default.
• W3035246543 hasConceptScore W3035246543C2780333948 @default.
• W3035246543 hasConceptScore W3035246543C2908647359 @default.
• W3035246543 hasConceptScore W3035246543C42219234 @default.
• W3035246543 hasConceptScore W3035246543C71924100 @default.
• W3035246543 hasConceptScore W3035246543C99454951 @default.
• W3035246543 hasFunder F4320307773 @default.
• W3035246543 hasIssue "1" @default.

• next